CD8A and cancer: These data indicate that NTP treatment elicits a more immunostimulatory anti‐cancer immune response profile, which persists to Day 14, as shown by higher IFN‐γ in CD3+ cells, lower ICOS+/PD1+ Tregs, and a higher CD8+/Treg ratio.